NCT07627074Recruiting
Weight Loss in Adults Using Semaglutide (Real-world Study)
Novo Nordisk A/S
Start Date
5/12/2026
Completion Date
6/1/2026
Summary
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Initiation of semaglutide for weight management during the study period.
* Age more than or equal to (≥) 18 at treatment initiation
* Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2.
* Other inclusion criteria as defined in the protocol are applicable.
Exclusion Criteria:
* Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
* Bariatric surgery at baseline.
* Diabetes at baseline.
* Pregnancy at baseline.
Interventions
DRUG
Semaglutide
Conditions
OverweightObesity
Locations
Novo Nordisk Investigational Site
Seattle, Washington 98039
United States
Novo Nordisk Investigational Site
London,
United Kingdom